Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 137 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Epigenetic Disorder Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

NCT06096688
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Completed No phase listed Observational

Prospective Natural History Study of Smoking, Immune Cell Profiles, Epigenetics and COVID-19

NCT04403386
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
30 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting Phase 1 Interventional

Venetoclax to Augment Epigenetic Modification and Chemotherapy

NCT05317403
View directory record Official record
Conditions
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Interventions
Venetoclax, Azacitadine, Vorinostat, Cytarabine, Fludarabine, Filgrastim
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Health Effects of Traditional Indigenous Chokeberry

NCT05410327
View directory record Official record
Conditions
Inflammation, Mental Health Wellness 1, Oxidative Stress
Interventions
Chokeberry (Aronia melanocarpa) juice
Other
Lead sponsor
University of North Dakota
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2023 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting No phase listed Observational

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

NCT02146170
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, Thymic Epithelial Tumors
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine)

NCT01845805
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
oral azacitidine, Observation
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Identification and Validation of Epigenetic Biomarkers of PMDD

NCT06771583
View directory record Official record
Conditions
PMDD, Premenstrual Dysphoric Disorder (PMDD), Premenstrual Syndrome-PMS, Premenstrual Syndrome, Menstrual Cycle
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetic Markers of B-Cell Function in Low Birth Weight Infants

NCT00925925
View directory record Official record
Conditions
Low Birth Weight, Small for Gestational Age, Immunodeficiency
Interventions
Cord blood collection for analysis
Other
Lead sponsor
University of Utah
Other
Eligibility
Up to 2 Hours
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 11, 2015 · Synced Jul 23, 2026, 5:31 AM EDT
Enrolling by invitation No phase listed Observational

Physical Acvitiy in Pregnancy

NCT07356180
View directory record Official record
Conditions
Pregnant Women, Gestational Diabetes, Obese But Otherwise Healthy Participants, Overweight (BMI > 25), Gestational Diabetes Mellitus in Pregnancy
Interventions
Pregnancy Physical Activity Questionnaire (PPAQ)
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional

Phase I Epigenetic Priming Using Decitabine With Induction Chemotherapy in AML

NCT00538876
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
decitabine
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2011 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Epigenetic Therapy
Interventions
Azacitidine, Entinostat, Nivolumab, CC-486 300
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Jul 23, 2026, 5:31 AM EDT
Not listed No phase listed Observational

Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder

NCT03494738
View directory record Official record
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

DNA Methylation and Vascular Function

NCT03527420
View directory record Official record
Conditions
Obesity, Vascular Dysfunction
Interventions
Exercise training
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Terminated Phase 1 Interventional

Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib

NCT01876641
View directory record Official record
Conditions
Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
Interventions
Vemurafenib + Cobimetinib, Decitabine
Drug
Lead sponsor
Mohammed M Milhem
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Jul 23, 2026, 5:31 AM EDT
Recruiting No phase listed Observational

cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer

NCT07224815
View directory record Official record
Conditions
CRC (Colorectal Cancer)
Interventions
cfDNA 5mC/5hmC Sequencing (EpiCORE Discovery Phase), EpiCORE Assay (Targeted Sequencing / qPCR Validation)
Diagnostic Test
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Results available

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903
View directory record Official record
Conditions
Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors, Ovarian Epithelial Cancer
Interventions
RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Drug
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
10
States / cities
Palo Alto, California • West Haven, Connecticut • South Bend, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency

NCT02691611
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1 Interventional Results available

Epigenetic Reprogramming in Relapse/Refractory AML

NCT03263936
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Decitabine, Vorinostat, Filgrastim (G-CSF), Fludarabine, Cytarabine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 25 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
28
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 23, 2026, 5:31 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

NCT06907875
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
EPI-321
Biological
Lead sponsor
Epicrispr Biotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 5:31 AM EDT
Withdrawn Phase 2 Interventional

Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS

NCT02204020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
5-azacytidine (5-aza) maintenance therapy after transplant
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Salivary Biomarkers for Concussion Recovery

NCT05379920
View directory record Official record
Conditions
Concussion, Brain
Interventions
High Volume Aerobic Exercise, Low Volume Aerobic Exercise
Behavioral
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
13 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 23, 2026, 5:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Salivary miRNA Diagnostic Test for Autism

NCT02832557
View directory record Official record
Conditions
Autism Spectrum Disorder, Developmental Delay
Interventions
Salivary collection, Vineland Adaptive Behavior Scale-III Assessment, Medical history questionaire, Autism Diagnostic Observation Schedule -2nd edition (ADOS-2), Mullen Scales of Early Learning
Other
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
24 Months to 48 Months
Enrollment
998 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2023 · Synced Jul 23, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation

NCT03319173
View directory record Official record
Conditions
Mild Cognitive Impairment, Metabolic Syndrome
Interventions
Dietary intervention
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Maple Grove, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Jul 23, 2026, 5:31 AM EDT